
These Milestones celebrate two decades of breakthroughs in basic, translational and clinical research which have revolutionised our understanding and management of cancer. This Milestone:
- Explores the first identified mechanisms of resistance to targeted treatments.
- Reports on the first trial to show that a bivalent vaccine for HPVs 16 and 18 could reduce cervical cancer risk.
- Highlights the papers that reported that defects in BRCA1 or BRCA2 are synthetically lethal with loss of PARP function.
- Explores the first whole-genome sequence of a cancer.
- Reports on the first papers to show mutations in histones in paediatric high-grade gliomas.
- Describes the landmark discovery that the gut microbiome is a modulator of response to cancer therapies.
View the interactive timeline >>
View the Collection of papers >>
Nature Portfolio is pleased to acknowledge financial support from Illumina, Inc, Johnson & Johnson and grant support from AstraZeneca, Boehringer Ingelheim International GmbH, and Merck & Co., Inc., Kenilworth, NJ, USA in producing this Nature Milestone.
Follow the Topic
-
Nature Medicine
This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.
-
Nature Genetics
This journal publishes the very highest quality research in genetics, encompassing genetic and functional genomic studies on human and plant traits and on other model organisms.
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in